

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): November 26, 2019**

---

**GALECTIN THERAPEUTICS INC.**

(Exact name of registrant as specified in its charter)

---

Nevada  
(State or Other Jurisdiction  
of Incorporation)

001-31791  
(Commission  
File Number)

04-3562325  
(IRS Employer  
Identification No.)

4960 PEACHTREE INDUSTRIAL BOULEVARD, STE 240  
NORCROSS, GA 30071

(Address of principal executive office) (zip code)

Registrant's telephone number, including area code: (678) 620-3186

N/A

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock \$0.001par value per share	GALT	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**SECTION 8 – OTHER ITEMS****Item 8.01 Other Items.**

On November 26, 2019, the Company issued the press release attached hereto as Exhibit 99.1.

**SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS****Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits. The following exhibit is filed with this Report:

<u>Exhibit No.</u>	<u>Description</u>
99.1	<a href="#">Press release</a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Galectin Therapeutics Inc.

Date: November 26, 2019

By: /s/ Jack W. Callicutt  
Jack W. Callicutt  
Chief Financial Officer

### **Galectin Therapeutics to Webcast Corporate Update on December 4, 2019 after Annual Meeting of Stockholders**

NORCROSS, Ga., November 26, 2019 (GLOBE NEWSWIRE) — **Galectin Therapeutics Inc.** (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that Harold H. Shlevin, Ph.D., president and chief executive officer, will present a corporate update via live webcast immediately following the business portion of its 2019 Annual Meeting of Stockholders. The webcast is expected to commence at approximately 9:30 a.m. ET on Wednesday, December 4, 2019.

The webcast can be accessed via the investor relations portion of the Galectin Therapeutics website at <http://investor.galectintherapeutics.com/>. The presentation can be heard via teleconference by dialing 866-225-1342 (within the United States). A list of international dial-in numbers can be found [here](#). The passcode for participants is 2856445641.

Please log in approximately 10 minutes before the event to ensure a timely connection. You may also test your connection prior to the start of the presentation by visiting: [https://dentons.adobeconnect.com/galt\\_board](https://dentons.adobeconnect.com/galt_board). The webcast will be archived on the Company's website.

For stockholders in attendance, there will be a question and answer period following the presentation at which pre-submitted written questions will be answered. Questions must be submitted via email by end of the day on Monday, December 2, 2019 to [ir@galectintherapeutics.com](mailto:ir@galectintherapeutics.com). The Company will cover as many submitted questions as possible in the time allotted.

### **About Galectin Therapeutics**

Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer.

Additional information is available at [www.galectintherapeutics.com](http://www.galectintherapeutics.com).

### **Contact**

Jack Callicutt, Chief Financial Officer  
(678) 620-3186  
[ir@galectintherapeutics.com](mailto:ir@galectintherapeutics.com)